Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty

Phase 4TerminatedNCT01475604

Amp Orthopedics, Inc.23 enrolled

Overview

The purpose of this study is to determine the effectiveness of pulsed radio frequency (PRF), a type of electromagnetic field treatment with the Ivivi Torino II for reducing post-operative narcotic use in patients recovering from Total Knee Arthroplasty.

Surgeons are continually looking for means to minimize postoperative pain following TKA in order to reduce or eliminate the need for opioid pain medications. Reductions in pain and edema along with improvements in range of motion encourage quicker recovery of joint function and normal activities. Pulsed radio frequency (PRF), a type of electromagnetic field treatment is proven to effectively modulate postoperative pain and edema in plastic surgery. Therefore, PRF has potential as an adjunct therapy for patients recovering from TKA. The purpose of the current double-blind, randomized, sham-controlled clinical trial is to determine the effectiveness and safety of the Ivivi Torino II, a device that delivers pulsed radio frequency (PRF), a type of electromagnetic field treatment, in patients recovering from TKA for treatment of severe knee OA.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Osteoarthritis, Knee

Interventions

Ivivi Torino IIDEVICE

Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery

Ivivi Torino IIDEVICE

Sham treatment for 4 weeks post-surgery

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 40 to 80 years * Primary diagnosis of knee OA * Appropriate candidate for TKA * Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects * Consent to the study and willing to comply with study product and methods including follow-up Exclusion Criteria: * Body mass index \> 40 kg/m2 * Scheduled for bilateral TKA * Advanced hip, spine, or ankle osteoarthritis that significantly limits ambulation * Subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverter-defibrillator) * Use of narcotic pain medication for any condition in the last 1 month prior to surgery * Self-reported diagnosis of post-traumatic or inflammatory arthritis (e.g. rheumatoid or psoriatic) * Pregnant or lactating female * Participation in any clinical trial in the past 30 days * Vulnerable populations including prisoners and nursing home residents * Any medical condition that, in the opinion of the investigator, may compromise patient safety or confound the assessment of treatment effectiveness

Locations (1)

Anderson Orthopaedic Research Institute

Alexandria, Virginia, United States

Outcomes

Primary Outcomes

The average daily morphine equivalent dose consumption at 2 weeks post-surgery.

Time frame: 2-week follow-up period from surgery

Secondary Outcomes

Post-surgical opioid use during hospitalization and following discharge at 1 and 4 weeks post-surgery.

Time frame: 1 and 4 weeks post-surgery

Knee pain severity assessed on a 10 cm visual analogue scale (VAS)

Knee pain will be assessed for "current", pain at the time of data collection and "maximum", maximum pain experience at any point during the day of evaluation

Time frame: At intervals over the 4-week follow-up period

The measurement of knee joint circumference

With patient in supine position, the circumference of the extended knee will be measured 1 cm proximal to the base of the patella using the same type of tape measure in all patients

Time frame: Measurement performed preoperatively, on the first or second postoperative day, at the discharge dressing change, and at the 4 week follow-up visit

Range of motion of the knee joint, assessed using the knee flexion technique

Range of motion will be assessed using the knee flexion technique, which allows the use of a goniometer with the trans-epicondylar axis of the knee joint as the fulcrum.

Time frame: Assessed preoperatively, on the first or second postoperative day, at the discharge dressing change (unless discharged within 2 days), and at the 4 week follow-up visit

OA-related medication use including analgesics, anti-inflammatories, and other non-opioids

Subjects will be required to track daily OA-related medication use including analgesics, anti-inflammatories, and other non-opioids using a daily diary.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.